ACTRN12623001024639尚未招募Unknown
A mixed-methods randomised, 12-week cross-over randomised controlled trial to establish the feasibility, acceptability, and preliminary effectiveness of two dietary interventions (prepared meals and meal kits) vs a control condition (Coles/Myer vouchers) in community-based people living with schizophrenia who are overweight or obese.
适应症
试验速览
- 阶段
- Unknown
- 状态
- 尚未招募
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 64 Years（—）
- 性别
- All
入选标准
- •1.Aged between 18 and 64 years (inclusive)
- •2.Consumer Integrated Mental Health and Addiction (CIMHA) diagnosis of schizophrenia or schizoaffective disorder
- •3.BMI greater than or equal to 25kg/m2 at baseline
- •4.Have had less than 5% body weight increase or loss in the previous 3 months
- •5.Live in independent accommodation with access to a kitchen with relevant appliances and accessories
- •6.Agree to participate, has capacity to consent and able to follow the study instructions and procedures.
排除标准
- •1.Acute psychiatric symptoms requiring immediate hospitalisation
- •2.Obesity induced by other endocrinologic disorder (e.g., Cushing Syndrome, untreated Hypothyroidism);
- •3.Previous surgical treatment of obesity
- •4.Current or prior history with risk of relapse, of a severe eating disorder
- •5.Any dietary allergies which preclude from safe consumption of provided meals or foods
- •6.Living with someone who prepares meals for them.
研究者
相似试验
进行中（未招募）
不适用
A randomised, controlled, 4-week, cross-over study assessing the efficacy and safety of adding oral morphine IR 10mg or sublingual buprenorphine 0.2mg on demand to a treatment with transdermal buprenorphine 35µg/H in non-malignant chronic low back pain.lumbalgieEUCTR2004-002311-91-BEniversity Hospital Ghent40
已完成
不适用
Optimal diet patterns for improving muscle strength in older adultsoss of muscle mass and strength in agingLoss of muscle mass and strength in agingMusculoskeletal - Other muscular and skeletal disordersACTRN12612000177853niversity of South Australia135
进行中（未招募）
不适用
A 12-week Study to Compare the Efficacy and Safety of Fixed Combinations of Fenofibrate /Simvastatin 145/20mg and Fenofibrate / Simvastatin 145/40mg Tablets versus Fenofibrate or Simvastatin Monotherapies in Subjects with Abnormal Levels of Fats(lipids) in the Blood and at High Risk of Cardiovascular Disease.MedDRA version: 15.1Level: LLTClassification code 10058110Term: DyslipidemiaSystem Organ Class: 100000004861DyslipidemiaEUCTR2011-005924-16-PLAbbott Laboratories Ireland Limited600
进行中（未招募）
不适用
A 12-week Study to Compare the Efficacy and Safety of Fixed Combinations of Fenofibrate /Simvastatin 145/20mg and Fenofibrate / Simvastatin 145/40mg Tablets versus Fenofibrate or Simvastatin Monotherapies in Subjects with Abnormal Levels of Fats(lipids) in the Blood and at High Risk of Cardiovascular Disease.DyslipidemiaMedDRA version: 14.1Level: LLTClassification code 10058110Term: DyslipidemiaSystem Organ Class: 100000004861EUCTR2011-005924-16-CZAbbott Laboratories Ireland Limited600
已完成
4 期
A 12-week randomized, controlled trial to compare TOUJEO® and TRESIBA® in terms of glucose values in target range and variability during continuous glucose monitoring in patients with type 1 diabetes mellitusNL-OMON48426Sanofi-aventis45